Onabotulinum May Decrease Opioid Use, Reduce Severity and Frequency of Nonmigraine Headache
In patients with chronic nonmigraine headaches, onabotulinum toxin type A injections may reduce pain severity and frequency of headaches.
In patients with chronic nonmigraine headaches, onabotulinum toxin type A injections may reduce pain severity and frequency of headaches.
Many patients with craniofacial pain syndromes such as trigeminal neuralgia, cluster headache, and migraine have an adequate response to pharmacologic therapies.
Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.
The presence of psychiatric disorders in patients with idiopathic intracranial hypertension is associated with poor treatment outcomes.
Fremanezumab was found to be effective and well-tolerated in patients with migraine who have failed to respond to prior preventive treatment.
Headache specialist was more likely to use triptans, while non-headache specialists and the headache specialist started prophylaxis at similar rates in eligible participants.
Revised criteria from the third edition of the International Classification of Headache Disorders (ICHD-3), can differentiate between chronic cluster headache (CCH) and episodic cluster headache (ECH) and may increase the number of CCH diagnoses.
The authors refute a systematic review and meta-analysis of literature on greater occipital nerve block for the treatment of chronic migraine headaches by Shauly and colleagues and published in Plastic and Reconstructive Surgery, citing extensive limitations and claiming the study ultimately raises more questions than answers.
Women with vs without frequent episodic tension-type headache (TTH) may have greater nerve sensitivity in response to mechanical stimuli, according to a study in Musculoskeletal Science and Practice. In this case-control, cross-sectional analysis, 32 consecutive women with TTH and 32 age-matched control individuals without a history of headache over the previous year were recruited from…
Treatment with lasmiditan was found to be associated with higher rates of freedom from pain and total migraine freedom compared with placebo in patients with migraine.